Short-Term Effect Of Ceriter Stride One (CSO) on FOG and Falling in pwP

Parkinson Disease Clinical Trial

— CSO_FOG  

Official title:

Exploration of the Short-term Effects and User Satisfaction of the Ceriter Stride One (CSO) Regarding the Prevention and Treatment of Freezing or Gait in Persons With Parkinson's Disease (pwP).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06204081
• Other study ID #: ONZ - 2023 - 0501
• Status: Recruiting
• Phase: N/A
• Start date: December 5, 2023
• Est. completion date: September 15, 2024

Study information

• Verified date: March 2024
• Source: University Ghent
• Contact: Wim De Wilde, MSc
• Phone: +32472575808
• Email: Wim.dewilde[@]ugent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Ceriter Stride One (CSO) is a "smart sole" with pressure sensors. The sole allows data on the displacement of the body's centre of gravity (COG), as well as spatiotemporal parameters, to be obtained via pressure recordings. Logarithms, released on the data captured by the sole, make it possible to recognise propulsion (forward movement of the CG), accompanied by a reduction in step length (festination) or feet remaining standing (freezing of gait). When the system registers incipient propulsion, an audio signal ("stop") is generated via an audio device and app on the mobile phone. The CSO aims to make the pwP stop before balance disturbance can occur, preventing further propulsion and falls. The aim of the study is to explore the short-term effects of the CSO in terms of reducing (preventing) freezing of gait and fall risk in a pilot group of pwP whose functionality is limited (Hoehn and Yahr 4). Short-term impact on gait (episodes of freezing of gait, mean step length, mean gait speed) will be evaluated and user satisfaction surveyed.

Description:

There is scientific evidence for making pwP stop at the onset of propulsion (when step length decreases and step frequency increases) in order to get the COG back within the base of support. Similarly, (auditory) cues are recommended to facilitate starting. These principles are implemented with the CSO : the device makes the pmP stop at onset of propulsion and generates an auditory, rhythmic cue to facilitate starting and walking with larger steps (prevention). This is an innovative application, not a standard-of-care intervention. Protocol : 20 persons with Parkinson's disease (H&Y 4) (attending physical therapy at Movita). The test proceeds in 3 stages : preparation / gait test / subjective evaluation : Preparation - Info / IC - General data : age, sex, number of years since diagnosis, use of aids, medication, fall incidents last week (fall diary based on fall diary), (last intake) medication and current efficacy (VAS). - MDS-UPDRS-II (degree of dependence), nFOGQ, Montreal Cognitive Assessment (MOCA). Clinical gait test : The soles are placed in the patient's shoes. If the patient uses an assistive device in daily life, the test is performed with an assistive device. Following procedure is done in a randomized order*: - Walking without auditory cue: for 3 minutes, the patient is asked to walk back and forth at a comfortable pace on a 4-meter course through a doorway (start : 2 meters before the doorway, stop : 2 meters beyond the doorway) without any auditory support. If no freezing occurs during this period, pwP is asked to turn 360° in the doorway. The first 1.5 minutes gait is performed without a double task, the next 1.5 minutes with a cognitive double task (100 - 3 = ... - 3 = ... -3 = ...). - Walking with auditory cues: for 3 minutes the patient is asked to walk back and forth at a comfortable pace along a 4-meter course through a doorway (start : 2 meters in front of the doorway, stop : 2 meters beyond the doorway) with auditory cues given at the occurrence of a freeze. If no FOG occured, the pwP is asked to turn 360° in the doorway. The first 1.5 minutes gait is performed without a dual task, the next 1.5 minutes with a cognitive dual task (100 - 3 = ... - 3 = ... -3 = ...). After each condition (with - without auditory cueing) a short break (2 minutes) is taken, during which a Borg scale for fatigue is taken. After the second condition, satisfaction with the effect of the aid is questioned (see below). The entire gait test is filmed (by a 2nd person). In this way data, including the number of freezing episodes, can be checked. *Randomization of conditions: per 2 patients. The first patient draws a card indicating whether or not the patient starts with auditory cues while walking. The 2nd patient then starts with the other condition, and so on. Thus we obtain 10 patients starting with the auditory cueing condition and 10 without. Parameters considered : duration/step, gait asymmetry (pressure of left foot vs. right foot), number of freezing periods, distance walked, number of steps, mean step length. Satisfaction questions - On a scale of 1 to 10, how would you rate the level of comfort of the Ceriter Stride One? - On a scale of 1 to 10, how safe do you feel when using the Ceriter Stride One? - To what extent do you feel more secure, on a scale of 1 to 10, while walking by using the Ceriter Stride One? - Open question : do you have any comments, concerns or questions of your own?

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 15, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Parkinson's disease (or other Parkinsonism)

• gait impairment with freezing of gait (FOG)
• 18-80 years old
• I.C. (informed consent)
• Montreal Cognitive Assessment (MoCA) >25

Exclusion Criteria:

• unable to walk 4m without assistance
• MoCA < 25
• no FOG

Related Conditions & MeSH terms

• Gait Disorders, Neurologic
• Gait, Festinating
• Parkinson Disease

Intervention

Device:
• CSO_without cueing
The sole is worn without using the cueing application
• CSO_cueing
The sole is worn with using the cueing application

Locations

Country	Name	City	State
Belgium	Ghent University	Gent	Oost-Vlaanderen

Sponsors (1)

Lead Sponsor	Collaborator
University Ghent

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Zoetewei D, Herman T, Brozgol M, Ginis P, Thumm PC, Ceulemans E, Decaluwe E, Palmerini L, Ferrari A, Nieuwboer A, Hausdorff JM. Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing o — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of captured episodes with freezing of gait (FOG)	n (number of captured FOG-episodes : the less, the better)	2 times 3 minutes
Primary	The number of captured steps	n (number - more steps relate to a better mobility)	2 times 3 minutes
Primary	The difference between the pressure of steps with left versus right foot; as a measure of gait asymmetry.	mean presure data of left foot versus mean pressure data of right foot	2 times 3 minutes
Primary	mean step length	mean step length (cm)	2 times 3 minutes
Secondary	users satisfaction	comfort and safety of the tool are questioned on a scale of 1 to 10.	after testing (5 min)

External Links

•   protocol of the DeFOG trial